Skip to main content

SuperMicrobiologists

Endotoxins: Recognition of Recombinant Tests by Pharmacopoeias – Where Do We Stand?

Published on 12 November 2025 4 min



In pharma, we all know that things usually move slowly…

Except right now, there’s real movement around recombinant bacterial endotoxin tests (BET) like rFC and rCR (previously called rLAL).

But how are these methods viewed by different pharmacopoeias?

Are they considered compendial methods or alternative methods?

To find out, we took a look at several pharmacopoeias, here’s what we found.


Discover the Top 3 Bacterial Endotoxin Test Suppliers

We asked the SuperMicrobiologists in a big survey.
Here’s what they said.

Compendial or Alternative Methods: What Do the Pharmacopoeias Say?

Here’s a summary table for the different pharmacopoeias:

rFC recombinant Factor CrCR recombinant full cascade
USP <86>
in-process, raw material,product with updated monograph
Compendial* Compendial* 
USP <86>
Product without updated monograph
compendial alternative methodcompendial alternative method
EU 2.6.32
in-process, raw material,product with updated monograph
CompendialAlternative
EU 2.6.32
Product without updated monograph
AlternativeAlternative
Indian 2.2.3AlternativeAlternative
Chinese ChP 9251AlternativeAlternative
Korean Test No. 23AlternativeAlternative
Brazilian 5.5.2.7.3AlternativeAlternative
Japanese G4-4-180AlternativeAlternative

* May require additional data for primary validation.




It’s clear that the U.S. Pharmacopoeia (USP) is currently the most advanced in recognizing recombinant methods.

However, one important point to note: as of the time of writing this article (June 2025), no monograph yet refers to chapter <86>.

So for now, recombinant methods are still considered alternative and must be validated as such.

Lack of Harmonization Between Pharmacopoeias

Likewise, even if you’re based in a country where the pharmacopoeia considers your method compendial, don’t forget to check the regulations in the countries where your products will be marketed.

If one of those countries doesn’t recognize the method as compendial, you’ll need to validate it as an alternative method.

This is the core issue with the lack of harmonization (for now) between pharmacopoeias regarding recombinant methods… but it’s probably only a matter of time!

Validation of Recombinant Methods: What Do the Pharmacopoeias Expect?

Now that we know whether a method is considered compendial or alternative, let’s look at how this affects the validation process.

Indeed, the biggest difference between a compendial method and an alternative method lies in how they must be validated.

Here’s a summary table of what pharmacopoeias may require during validation:

CompendialAlternativeCompendial alternative method
Method suitabilityComparison study with LALPrimary Validation
Method suitabilityComparison study with LAL
Method suitability

Validating an Alternative Method: A Simple and Quick Process

If the method you’ve chosen is considered alternative, don’t worry.

Based on discussions with several labs, validating a bacterial endotoxin test is nothing like validating a rapid microbiological method (RMM), which can take months or even years.

In this case, validating a product usually takes 2 to 3 days, with no more than 4 hours of work per day.


“Validating an alternative method for endotoxin testing isn’t that complicated.”

A SuperMicrobiologist

Practical Tip: Include Naturally Contaminated Samples in Your Validation

During validation, it’s common to work with endotoxin-spiked samples. But as with any artificial contamination, it doesn’t always reflect real-world conditions.

That’s why we recommend adding a few naturally contaminated product samples to your validation protocol.

Even though it’s not required by the pharmacopoeia, it will give you greater confidence in your detection method.



See, for example, the scientific publication by Kikuchi:

Collaborative Study of Bacterial Endotoxins Test Using Recombinant Factor C-Based Procedure for Detection of Lipopolysaccharides – 2023



The results clearly showed significant differences between naturally contaminated samples and those artificially spiked.

Conclusion: Recombinant BET Are Growing – Be Ready

Even though recombinant methods are not yet fully harmonized worldwide, they are increasingly recognized and represent a truly sustainable alternative to LAL.

More ethical, more stable, rFC and rCR tests are expected to become the new standard in the future.

In the meantime, it’s essential to clearly understand their regulatory status, adapt your validation strategy accordingly… and keep an eye on pharmacopoeial updates!

Tags

Leave a Reply

Your email address will not be published. Required fields are marked *